As with other classes of epigenetic agents, HDAC inhibitors demonstrate slightly higher clinical activity in patients with T cell lymphomas in combination than when administered as monotherapies. This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.